Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Interest & Investment Income (2016 - 2026)

Ocular Therapeutix has reported Interest & Investment Income over the past 14 years, most recently at $6.0 million for Q1 2026.

  • For Q1 2026, Interest & Investment Income rose 58.13% year-over-year to $6.0 million; the TTM value through Mar 2026 reached $20.6 million, up 1.94%, while the annual FY2025 figure was $18.4 million, 9.5% down from the prior year.
  • Interest & Investment Income for Q1 2026 was $6.0 million at Ocular Therapeutix, down from $7.3 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $7.3 million in Q4 2025 and troughed at $18000.0 in Q1 2022.
  • A 5-year average of $2.9 million and a median of $3.5 million in 2025 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: skyrocketed 6950.0% in 2022 and later crashed 42.76% in 2025.
  • Year by year, Interest & Investment Income stood at $423000.0 in 2022, then soared by 244.92% to $1.5 million in 2023, then surged by 220.15% to $4.7 million in 2024, then soared by 57.2% to $7.3 million in 2025, then fell by 17.61% to $6.0 million in 2026.
  • Business Quant data shows Interest & Investment Income for OCUL at $6.0 million in Q1 2026, $7.3 million in Q4 2025, and $3.7 million in Q3 2025.